Cancer Progress

nanoString Pfizer

We look forward to seeing you at the 26th Annual Cancer Progress Conference on March 17-18 at the Grand Hyatt
New York in New York City!


Since 1985, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference.

Our 26th Annual Meeting on March 17-18, 2015 will  provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference. Confirmed speakers as of December 1st, 2014 are:

  • Omar Abdel-Wahab, MD, Memorial Sloan Kettering Cancer Center
  • Peter C. Adamson, MD, The Children’s Hospital of Philadelphia
  • Rafael Amado, MD, GlaxoSmithKline
  • Peter Bach, MD, Memorial Sloan-Kettering Cancer Center
  • Robert A. Beckman, MD, Daiichi Sankyo Pharmaceutical
  • Jeff Bockman, PhD, Defined Health
  • Otis Webb Brawley, MD, FACP, American Cancer Society
  • Renier J. Brentjens, MD, PhD, Memorial Sloan Kettering Cancer Center
  • Lynda Chin, MD, MD Anderson Cancer Center
  • Meredith K. Chuk, MD, FDA
  • Robert Cohen, MD, Calico Life Sciences
  • Barbara A. Conley, MD, NIH, Division of Cancer Treatment and Diagnosis
  • Louis J. DeGennaro, PhD, Leukemia & Lymphoma Society
  • Thomas O. Daniel, MD, Celgene Corporation
  • Kathleen A. Denis, PhD, The Rockefeller University
  • Kapil Dhingra, MD, KAPital Consulting LLC
  • James H. Doroshow, MD, National Cancer Institute
  • Thomas J. Farrell, Bellicum Pharmaceuticals
  • Sean Ferree, PhD, NanoString Technologies
  • Stanley R. Frankel, MD,
  • Richard Brian Gaynor, MD, Eli Lilly and Company
  • Robert H. Glassman, MD, Merrill Lynch
  • Jeremy P. Goldberg, JPG Healthcare LLC
  • Brad Gray, NanoStrings Technologies
  • William Grossman, MD, PhD, AbbVie
  • Ivan Horak, MD, Symphogen A/S
  • Axel Hoos, MD, PhD, GlaxoSmithKline
  • Johanna Joyce, PhD, Memorial Sloan Kettering Cancer Center
  • Thomas J. Kipps, MD, PhD, Moores UCSD Cancer Center
  • Michael Kolodziej, MD, Aetna
  • Amy Krie, MD, Avera Cancer Institute
  • Manfred Lehnert, MD, Takeda Pharmaceuticals International
  • Christoph Lengauer, MD, PhD, Blueprint Medicines
  • Hy Levitsky, MD, Roche Pharmaceuticals
  • Brian Leyland-Jones, MD, Avera Cancer Institute
  • Nils Lonberg, PhD, Bristol-Myers Squibb
  • Patricia LoRusso, D.O., Smilow Cancer Center, Yale University
  • Franziska Michor, PhD, Harvard School of Public Health
  • Ronnie Morris, MD, Champions Oncology
  • Lee Newcomer, MD, MHA, United Healthcare
  • Larry Norton, MD, Memorial Sloan Kettering Cancer Center
  • Mike Rice, MS, MBA, Defined Health
  • Dr. Harlan Robins, PhD, Adaptive Biotechnologies
  • Carlos Rodriguez-Galindo, MD, Harvard Medical School
  • Noemi Rosa, GlaxoSmithKline
  • Neal Rosen, MD, PhD, Memorial Sloan Kettering Cancer Center
  • Raphaël F. Rousseau, MD, PhD, Genentech Inc.
  • Eric Rowinsky, MD, Stemline Therapeutics
  • Rob Ruijtenbeek, PamGene BV
  • Peter Sandor, MD, MBA, Amgen, Inc.
  • Prof. Dolores J. Schendel, PhD, Medigene
  • Cecelia Schott, Pharm D, MBA, AstraZeneca
  • Wendy K.D. Selig, Melanoma Research Alliance
  • Jeffrey Settleman, PhD, Genetech
  • Angela Shen, MD, MBA, Novartis Pharmaceuticals Corp.
  • Ellen V. Sigal, PhD, Friends of Cancer Research
  • Mark J. Simon, Torreya Partners LLC
  • Eric Slosberg, PhD, Novartis Oncology
  • John J. Sninsky, PhD, Quest Diagnostics
  • David Solit, MD, Memorial Sloan Kettering Cancer Center
  • Chris H. Takimoto, MD, PhD, Janssen Research & Development
  • Marc Theoret, MD, FDA
  • Alain Thibault, MD, arGEN-X N.V.
  • Jedd Wolchok, MD, PhD, Memorial Sloan-Kettering Cancer Center
  • Cassian Yee MD, MD Anderson Cancer Center
  • Jerome Zeldis, MD, PhD, Celgene Corporation

We look forward to seeing you at the 26th Annual Cancer Progress Conference on March17-18 at the Grand Hyatt New York in New York City!